NCT07704372RecruitingPhase 2
Superoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck Cancer
Superoxide Dismutase Skin Spray for Reducing Acute Radiation Dermatitis in Patients With Head and Neck Cancer Undergoing Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
To evaluate the efficacy and safety of superoxide dismutase skin spray for the reducing the acute radiation dermatitis in patients with head and neck malignancies undergoing radiotherapy.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- First submitted
- 3 Jul 2026
- Start date
- 28 Sept 2026
- Primary completion date
- 31 Jan 2027
- Lead sponsor
- West China Hospital
- Diseases
- Head and neck cancer
- NCT number
- NCT07704372
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 140
- From 28 Sept 2026 to the primary completion date, 31 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Pre-existing skin disease or open wounds in the irradiation field.
- Have a history of head and neck radiotherapy.
- Autoimmune or connective tissue disorders affecting skin.
- Known allergy to any component of study formulations.
- Any condition that, in the investigator's judgment, would interfere with study participation or outcome assessment.
Who the study is looking for
- Histologically confirmed malignant tumors of the head and neck without distant metastasis.
- Scheduled to undergo either postoperative adjuvant radiotherapy or definitive radiotherapy, with or without concurrent chemotherapy.
- Age 18-80 years at the time of consent.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Signed informed consent form.
- Adequate cognitive and reading abilities to complete the questionnaire.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sichuan University West China Hospital Coordinator of this site? Confirm its status | Chengdu | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.